Michael S Stalvey1, Jesse Pace2, Minoo Niknian3, Mark N Higgins4, Valerie Tarn5,2, Joy Davis6, Sonya L Heltshe7,8, Steven M Rowe6. 1. Department of Pediatrics, mstalvey@peds.uab.edu. 2. Pediatric Pulmonary Center, and. 3. Vertex Pharmaceuticals Incorporated, Boston, Massachusetts. 4. Vertex Pharmaceuticals (Europe) Ltd, London, United Kingdom. 5. Department of Pediatrics. 6. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 7. Department of Pediatrics, University of Washington, Seattle, Washington; and. 8. CF Foundation Therapeutics Development Network, Seattle Children's Research Institute, Seattle, Washington.
Abstract
BACKGROUND AND OBJECTIVES: Cystic fibrosis (CF) is known for its impact on the lung and pancreas of individuals; however, impaired growth is also a common complication. We hypothesized that targeting the biological defect in the CF transmembrane conductance regulator (CFTR) protein may affect growth outcomes. METHODS: In this post hoc analysis, we assessed linear growth and weight in 83 children (aged 6-11 years) enrolled in 2 clinical trials, the longitudinal-observation GOAL study and theplacebo-controlled ENVISION study, to evaluate the effects of ivacaftor, a CFTR potentiator. We calculated height and weight z scores and height and weight growth velocities (GVs). RESULTS: In ivacaftor-treated children in GOAL, height and weight z scores increased significantly from baseline to 6 months (increases of 0.1 [P < .05] and 0.26 [P < .0001], respectively); height GV increased significantly from 3 to 6 months (2.10-cm/year increase; P < .01). In ivacaftor-treated children in ENVISION, height and weight z scores increased significantly from baseline to 48 weeks (increases of 0.17 [P < .001] and 0.35 [P < .001], respectively). Height and weight GVs from baseline to 48 weeks were also significantly higher with ivacaftor than with placebo (differences of 1.08 cm/year [P < .05] and 3.11 kg/year [P < .001], respectively). CONCLUSIONS:Ivacaftor treatment in prepubescent children may help to address short stature and altered GV in children with CF; results from these analyses support the existence of an intrinsic defect in the growth of children with CF that may be ameliorated by CFTR modulation.
RCT Entities:
BACKGROUND AND OBJECTIVES:Cystic fibrosis (CF) is known for its impact on the lung and pancreas of individuals; however, impaired growth is also a common complication. We hypothesized that targeting the biological defect in the CF transmembrane conductance regulator (CFTR) protein may affect growth outcomes. METHODS: In this post hoc analysis, we assessed linear growth and weight in 83 children (aged 6-11 years) enrolled in 2 clinical trials, the longitudinal-observation GOAL study and the placebo-controlled ENVISION study, to evaluate the effects of ivacaftor, a CFTR potentiator. We calculated height and weight z scores and height and weight growth velocities (GVs). RESULTS: In ivacaftor-treated children in GOAL, height and weight z scores increased significantly from baseline to 6 months (increases of 0.1 [P < .05] and 0.26 [P < .0001], respectively); height GV increased significantly from 3 to 6 months (2.10-cm/year increase; P < .01). In ivacaftor-treated children in ENVISION, height and weight z scores increased significantly from baseline to 48 weeks (increases of 0.17 [P < .001] and 0.35 [P < .001], respectively). Height and weight GVs from baseline to 48 weeks were also significantly higher with ivacaftor than with placebo (differences of 1.08 cm/year [P < .05] and 3.11 kg/year [P < .001], respectively). CONCLUSIONS:Ivacaftor treatment in prepubescent children may help to address short stature and altered GV in children with CF; results from these analyses support the existence of an intrinsic defect in the growth of children with CF that may be ameliorated by CFTR modulation.
Authors: J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Douglas N Homnick; Benjamin D Homnick; Andrew J Reeves; John H Marks; Ronald S Pimentel; Sally K Bonnema Journal: Pediatr Pulmonol Date: 2004-08
Authors: Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan Journal: J Pediatr Date: 2015-09-02 Impact factor: 4.406
Authors: Sara Pagani; Elena Bozzola; Gloria Acquafredda; Vito Terlizzi; Valeria Raia; Fabio Majo; Alberto Villani; Mauro Bozzola Journal: Clin Med Res Date: 2019-08-28
Authors: Jennifer Guimbellot; George M Solomon; Arthur Baines; Sonya L Heltshe; Jill VanDalfsen; Elizabeth Joseloff; Scott D Sagel; Steven M Rowe Journal: J Cyst Fibros Date: 2018-04-21 Impact factor: 5.482
Authors: John Paul Clancy; Calvin U Cotton; Scott H Donaldson; George M Solomon; Donald R VanDevanter; Michael P Boyle; Martina Gentzsch; Jerry A Nick; Beate Illek; John C Wallenburg; Eric J Sorscher; Margarida D Amaral; Jeffrey M Beekman; Anjaparavanda P Naren; Robert J Bridges; Philip J Thomas; Garry Cutting; Steven Rowe; Anthony G Durmowicz; Martin Mense; Kris D Boeck; William Skach; Christopher Penland; Elizabeth Joseloff; Hermann Bihler; John Mahoney; Drucy Borowitz; Katherine L Tuggle Journal: J Cyst Fibros Date: 2018-06-20 Impact factor: 5.482
Authors: Catherine M McDonald; Jessica A Alvarez; Julianna Bailey; Ellen K Bowser; Kristen Farnham; Mark Mangus; Laura Padula; Kathleen Porco; Mary Rozga Journal: J Acad Nutr Diet Date: 2020-06-19 Impact factor: 5.234
Authors: Scott D Sagel; Umer Khan; Sonya L Heltshe; John P Clancy; Drucy Borowitz; Daniel Gelfond; Scott H Donaldson; Antoinette Moran; Felix Ratjen; Jill M VanDalfsen; Steven M Rowe Journal: Ann Am Thorac Soc Date: 2021-01
Authors: J S Guimbellot; A Baines; A Paynter; S L Heltshe; J VanDalfsen; M Jain; S M Rowe; S D Sagel Journal: J Cyst Fibros Date: 2020-11-25 Impact factor: 5.482